Quarterly report pursuant to Section 13 or 15(d)

Commitments and contingencies (Details Narrative)

v3.24.3
Commitments and contingencies (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
Jul. 11, 2023
Aug. 27, 2021
Oct. 31, 2022
Sep. 30, 2022
Aug. 31, 2022
Jun. 30, 2020
Sep. 30, 2024
Law suit filing date             May 28, 2019
G Farma Settlors [Member]              
Litigation settlement amount awarded from other party $ 2,539,597           $ 2,539,597
Litigation settlement default amount 2,494,450            
Interest receivable 40,219           $ 311,014
Litigation settlement costs 1,643            
Attorneys fee $ 3,285            
Debt instrument, interest rate, effective percentage 10.00%            
Settlement Agreement and Mutual Release [Member] | G Farma Settlors [Member]              
Liability for unpaid claims and claims description   The Settlement Agreement requires the G Farma Settlors to pay the Company an aggregate of $500,000 plus interest, payable monthly as follows: (i) $500 per month for 12 months beginning on September 5, 2021, (ii) $1,000 per month for 12 months beginning September 5, 2022, (iii) $2,000 per month for 12 months beginning September 5, 2023, and (iv) increasing by an additional $1,000 per month on each succeeding September 5th thereafter, until the settlement amount and accrued unpaid interest is paid in full. Interest on the unpaid balance shall initially accrue at the rate of 4.25%, commencing February 25, 2021, and shall be adjusted on February 25th of each year to equal the Prime Rate as published in the Wall Street Journal plus 1%.          
Liability for unpaid claims and claims adjustment expense, net   $ 500,000 $ 500,000 $ 500,000 $ 500,000    
Liability for unpaid claims     2,000,000 2,000,000 2,000,000    
Remaining amount     494,450 494,450 494,450    
Liability for accrued unpaid interest     $ 2,000,000 $ 2,000,000 $ 2,000,000    
G FarmaLabs Limited [Member]              
Sale leaseback transaction, net book value           $ 622,670  
Loss contingency receivable, proceeds           $ 249,481